WDNA WisdomTree BioRevolution Fund

ETF 23.50 Delayed

ETF quote, holdings, sector allocation, technicals, and options analytics. Expected move IV rank history Fibonacci levels

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

WDNA $23.50 —
Key stats
$23.50
52-Week Range
$15.67 – $24.74
YTD
+38.89%
IV Rank (30D)
12.01
Straddle Price
$2.40
P/C Vol Ratio
0.00
Open
$23.49
Day Range
$23.44 – $23.62
Volume
1,684
Prev Close
$22.60
About

WisdomTree BioRevolution Fund (WDNA) ETF

No description available.

Exchange
BATS
Inception
2021-06-01
Has Options
Yes
Fund profile
holdings as of Jun 30, 2026SEC filingthrough Jun 2026flows, SEC filings
Thematic Biotech & Health Innovation#20 of 26 by assets WisdomTree US Index-tracking
Expense ratio
0.45%
prospectus, filed Oct 28, 2025
Assets
$4.7M
shares × price, Oct 9, 2026
Trailing yield
3.28%
paid annual
Average daily volume
$69K
30 sessions
Holdings
81
top 10 are 30.7%
Listed
Jun 1, 2021
Cboe BZX
Closure risk, 12 months
6.8%
low: trading volume, volatility · model
Tracking difference
-0.49 pts
vs index, after fees, FY 2026
FrenzyCap ETF score
41
how it is built
Cost74
Liquidity0
Scale0
Diversification77

Moves with. Small caps over large (13% of its variance, beta 0.78); US large-cap stocks (11% of its variance, beta 0.53); Long Treasuries (7% of its variance, beta 0.66); Bitcoin (4% of its variance, beta 0.07). These factors explain 40% of its daily moves over the last year.

Stated objective. The WisdomTree BioRevolution Fund (the Fund) seeks to track the price and yield performance, before fees and expenses, of the WisdomTree BioRevolution Index (the Index). (from the fund's prospectus)

All 81 holdingsFlow historySimilar fundsOverlap toolAll Biotech & Health Innovation ETFs

Fund flows
through Jun 2026SEC filings
Jun 2026
$0
latest reported month
Latest 3 months
$0
0.0% of assets
Latest 12 months
−$358K
−13.4% of assets
Jul 2025: $0Aug 2025: $0AugSep 2025: $0Oct 2025: $0OctNov 2025: $0Dec 2025: $0DecJan 2026: $0Feb 2026: −$358K−$358KFebMar 2026: $0Apr 2026: $0AprMay 2026: $0Jun 2026: $0Jun
View as a table
Net flows of WDNA by month, Jul 2025 to Jun 2026
MonthNet flow
Jun 2026$0
May 2026$0
Apr 2026$0
Mar 2026$0
Feb 2026−$358K
Jan 2026$0
Dec 2025$0
Nov 2025$0
Oct 2025$0
Sep 2025$0
Aug 2025$0
Jul 2025$0

Net creations and redemptions from the fund's SEC filings, which become public about 60 days after each quarter. Every month since 61 months ago

Similar funds
FundOverlapFeeAssets1Y
HELXFranklin Genomic Advancements ETF33%0.50%$32M+29.2%compare
XBIState Street SPDR S&P Biotech ETF33%0.35%$9.9B+45.8%compare
GNOMGlobal X Genomics & Biotechnology ETF30%0.50%$101M+63.4%compare
IBBiShares Biotechnology ETF29%0.44%$10.8B+35.9%compare
LABUDirexion Daily S&P Biotech Bull 3X ETF27%—$553M+123.0%compare

Ranked by how much of the two portfolios is the same securities.

Look-through: what the holdings say
weights as of Jun 30, 2026SEC filing
Holdings vs fair value
+5.0%
29% under, 31% over · 83% covered
Price / earnings
—
60% loss-making · 81% covered
Price / book · sales
3.5 · 4.6
revenue growth +8.5%
Above 200-day average
67%
51% above 50-day · by weight
Short interest
12.1%
of float, weighted · 5.3 days to cover
Insider buying
4%
of weight had net insider buying, 90 days; 55% net selling
13F holders
−0.2%
change in shares held by institutions, latest quarter
Reporting earnings
3.0%
of weight in 7 days; 6.2% in 14
Implied correlation
0.22
fund IV 34.2% vs holdings 69.2% · board
Largest contributors below fair value
STOK+50%BEAM+50%CTVA+50%IMNM+40%GPCR+41%
Largest contributors above fair value
MRNA−31%TWST−16%NTRA−34%TXG−18%CLDX−29%
Holdings reporting in the next 14 days · weighted implied move this week 0.11%
JNJ10/13 · 3.0% · ±3.6%TMO10/21 · 1.5% · ±3.1%ARGX10/22 · 0.9% · ±3.6%DHR10/21 · 0.7% · ±3.3%

Each figure is the fund's holdings weighted by position size, using our data on those stocks, and covers only the share of the stock holdings stated. Positive fair value means the holdings trade below our estimate.

What changed in the portfolio
Mar 31, 2026 → Jun 30, 2026
ActionHoldingWeight beforeWeight afterShares vs flows
IncreaseTWSTTWIST BIOSCIENCE CORP2.32%5.95%+41.7%
ExitFOLDAmicus Therapeutics Inc.2.19%——
IncreaseTEMTEMPUS AI INC0.78%2.28%+173.1%
ExitNovo Nordisk A/S1.49%——
IncreaseLLYELI LILLY & COMPANY2.64%4.08%+41.3%
DecreasePFEPFIZER INC2.74%1.34%−31.7%
ExitACLXArcellx Inc1.28%——
IncreaseTMOTHERMO FISHER SCIENTIFIC INC0.26%1.52%+581.4%
IncreaseBIOHAVEN LTD0.15%1.37%+541.8%
DecreaseBNTXBIONTECH SE2.09%0.88%−52.3%

7 new, 11 exited, 21 increased and 17 decreased between the fund's two latest holdings reports; turnover 22.8%. Full holdings and history

Under the hood
fiscal year to Jun 30, 2026SEC census
Authorized participants
1 active
of 21 with agreements; top 3 did 100%
Created · redeemed
$0 · $358K
over the fiscal year
Redemptions in kind
101%
creations 100% in kind
Creation unit
10,000
shares
Securities lending
19.20%
of assets on loan on average; earned 9.1 bp
Return vs index
-0.49 pts
after fees; -0.04 before; daily s.d. 0.42
Diversification status
Non-diversified
may concentrate in fewer issuers

From the fund's annual census filing with the SEC. In-kind redemptions are what let an ETF shed appreciated securities without realising gains.

ETF Profile
holdings as of 2026-06-30
Holdings
87
AUM
$2.7M
Provider
Nport
Inception
2021-06-01
Exchange
BATS
Data As Of
2026-06-30
Expense Ratio
0.45%
Dividend Yield
3.28%
Distribution
Annual
Recent distributions
Ex-Date Pay Date Amount Type
2025-12-26 2025-12-30 $0.7705 CD
2024-12-26 2024-12-30 $0.1071 CD
2023-12-22 2023-12-28 $0.1350 CD
2022-12-23 2022-12-29 $0.0653 CD
2021-12-27 2021-12-30 $0.0246 CD
Asset Allocation
Top Holdings
top 50 of 87 holdings
Symbol Name Weight % Asset Class Country
— DREY INST PREF GOV MM-M 6.87% Short-term investment US
GPCR Structure Therapeutics Inc 3.21% Equity (common) US
LLY Eli Lilly & Co 3.13% Equity (common) US
NTRA Natera Inc 2.93% Equity (common) US
JNJ Johnson & Johnson 2.68% Equity (common) US
MRNA Moderna Inc 2.66% Equity (common) US
STOK Stoke Therapeutics Inc 2.49% Equity (common) US
PFE Pfizer Inc 2.42% Equity (common) US
UTHR United Therapeutics Corp 2.32% Equity (common) US
RGNX REGENXBIO Inc 2.30% Equity (common) US
BNTX BioNTech SE 2.26% Equity (common) DE
AMGN Amgen Inc 2.21% Equity (common) US
IONS Ionis Pharmaceuticals Inc 2.20% Equity (common) US
FOLD Amicus Therapeutics Inc 2.19% Equity (common) US
— Novo Nordisk A/S 2.17% Equity (common) DK
AZN AstraZeneca PLC 2.15% Equity (common) GB
BEAM Beam Therapeutics Inc 2.14% Equity (common) US
— CRISPR Therapeutics AG 2.09% Equity (common) CH
— Novonesis Novozymes B 2.03% Equity (common) DK
IMNM Immunome Inc 1.85% Equity (common) US
GILD Gilead Sciences Inc 1.74% Equity (common) US
EXAS Exact Sciences Corp 1.59% Equity (common) US
TWST Twist Bioscience Corp 1.56% Equity (common) US
ARWR Arrowhead Pharmaceuticals Inc 1.54% Equity (common) US
KRYS Krystal Biotech Inc 1.53% Equity (common) US
— Novartis AG 1.52% Equity (common) CH
VRTX Vertex Pharmaceuticals Inc 1.39% Equity (common) US
TXG 10X Genomics Inc 1.39% Equity (common) US
GMAB Genmab A/S 1.28% Equity (common) DK
AGIO Agios Pharmaceuticals Inc 1.27% Equity (common) US
— Roivant Sciences Ltd 1.27% Equity (common) US
VCYT Veracyte Inc 1.20% Equity (common) US
CTVA Corteva Inc 1.18% Equity (common) US
REGN Regeneron Pharmaceuticals Inc 1.16% Equity (common) US
— uniQure NV 1.13% Equity (common) NL
ARGX Argenx SE 1.09% Equity (common) NL
— Bunge Global SA 1.09% Equity (common) US
BMRN BioMarin Pharmaceutical Inc 1.09% Equity (common) US
— Takeda Pharmaceutical Co Ltd 1.08% Equity (common) JP
BMY Bristol-Myers Squibb Co 1.08% Equity (common) US
DHR Danaher Corp 1.08% Equity (common) US
RGEN Repligen Corp 1.06% Equity (common) US
NTLA Intellia Therapeutics Inc 1.06% Equity (common) US
TEM Tempus AI Inc 1.03% Equity (common) US
VKTX Viking Therapeutics Inc 1.00% Equity (common) US
DAR Darling Ingredients Inc 1.00% Equity (common) US
ABSI Absci Corp 0.99% Equity (common) US
— Bayer AG 0.98% Equity (common) DE
— Zealand Pharma A/S 0.93% Equity (common) DK
SANA Sana Biotechnology Inc 0.91% Equity (common) US
Geographic Breakdown
Chart
Seasonality
'21'22'23'24'25'26Avg
Jan---14.76%5.83%-6.13%4.38%6.26%-0.88%
Feb---4.23%-6.44%7.59%-6.08%0.72%-1.69%
Mar--3.28%-0.34%-2.75%-5.64%-4.38%-1.97%
Apr---12.59%-0.60%-9.94%6.15%0.95%-3.21%
May---2.72%-1.50%1.58%-5.66%2.60%-1.14%
Jun6.91%-0.86%0.96%-2.22%8.44%13.68%4.49%
Jul-3.94%6.92%5.60%7.75%2.06%-5.86%2.09%
Aug4.94%-2.14%-8.09%1.15%3.63%18.60%3.02%
Sep-7.56%-8.52%-9.88%0.49%10.62%3.77%-1.85%
Oct0.36%5.13%-6.96%-4.50%5.08%-0.56%*-0.24%
Nov-8.09%3.00%10.48%2.38%4.68%--2.49%
Dec1.14%-6.81%8.79%-11.12%-0.74%---1.75%
Total-7.06%-31.35%-4.59%-16.38%28.32%38.82%1.29%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $23.37
SMA 50: $22.63
SMA 200: $19.34
Current: $23.50
EMA 12: $23.37
EMA 26: $23.19
MACD: 0.1732 | Signal: -0.1382
BULLISH
ADX (14): 24.69
WEAK TREND
+DI: 35.61
−DI: 23.43

Momentum Oscillators

RSI (14): 53.13
NEUTRAL
Stoch %K: 18.80
Stoch %D: 20.02
Williams %R: -56.62

Volume & Volatility

BB Upper: $24.63
BB Lower: $22.12
NEUTRAL
OBV: -5,988
Vol SMA 20: 1,653
Vol ROC: 26.90%
ATR: $0.56
True Range: $1.02
HV 20: 37.7%
HV 30: 33.1%
HV 60: 37.6%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-11T00:00:00 – 2026-10-09T00:00:00
AI Analysis

Click Frenzy-Pro™ for an AI analysis of this ticker.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

News
All WDNA news →

WDNA Options Activity & IV Rank

WDNA IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 34.2%
7-DTE IV: 51.9%
Expected Move: $2.40
7-DTE Move: $1.48
Days to Exp: 42 (2026-11-20)

Options Flow

Call Volume: 75
Put Volume: 0
P/C Volume: —
BULLISH
Call OI: 75
Put OI: 0
P/C OI: —
Total OI: 75

ATM Options Pricing

ATM Call: $1.32
ATM Put: $1.07
Call %: 5.6%
Put %: 4.6%

Chain Summary

Chain Volume: 76
Chain OI: 75
Last Updated: 10/9/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Oct 9 · No data
30 DTE / 10d —
— pts EXTREME
as of Oct 9 · No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)4.4LowOct 9
IV Rank (30 DTE)12.0LowOct 9
Straddle Price (30 DTE)$2.40Oct 9
Beta Analysis

Risk Metrics

Beta: 1.0207
Alpha: 17.66%
Correlation: 0.4563
R-Squared: 20.8%
Stock Volatility: 29.2%
Market Volatility: 13.0%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time

WDNA Institutional Ownership (13F)

Latest filings — 2026-06-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

3 filers923 shares$18.95K value
# Filer Shares Value % of Total % of Float Period
1 LANARK FINANCIAL, INC. 598 $12.31K 65.00% — 2026-06-30
2 OSAIC HOLDINGS, INC. Custodian 225 $4.63K 24.45% — 2026-06-30
3 Royal Bank of Canada Custodian 100 $2.00K 10.56% — 2026-06-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
7.78K
SI % of Float
3.89%
Days to Cover
5.11
Short Vol Ratio
38.0%
Free Float
—
Float %
—
Short interest 2026-09-30 • Short volume 2026-10-09
WDNA Constituent Performance

Click any bar to view the full quote for that stock.

WDNA Constituents (68 of 68)
Symbol Name Weight % Price 1 Day 1 Week 1 Month
GPCR Structure Therapeutics Inc 3.21% $25.54 -0.51%-7.70%-33.94%
LLY Eli Lilly & Co 3.13% $1179.27 +0.83%+3.19%+5.70%
NTRA Natera Inc 2.93% $400.71 +2.54%-2.35%+21.82%
JNJ Johnson & Johnson 2.68% $261.44 +1.93%+2.11%-1.56%
MRNA Moderna Inc 2.66% $225 +14.21%+18.41%+56.28%
STOK Stoke Therapeutics Inc 2.49% $24.74 +3.30%-3.43%-14.78%
PFE Pfizer Inc 2.42% $28.28 +1.65%+1.73%+2.02%
UTHR United Therapeutics Corp 2.32% $549.16 +3.07%+1.38%+10.47%
RGNX REGENXBIO Inc 2.30% $8.07 -0.25%+8.61%-5.39%
BNTX BioNTech SE 2.26% $96.96 +5.32%+0.06%+0.24%
AMGN Amgen Inc 2.21% $414.87 +1.82%+2.94%+9.94%
IONS Ionis Pharmaceuticals Inc 2.20% $45.28 +4.57%+4.00%-16.47%
FOLD Amicus Therapeutics Inc 2.19% $14.49 +0.21%+0.21%+0.42%
AZN AstraZeneca PLC 2.15% $159.2 +0.26%+1.47%-0.61%
BEAM Beam Therapeutics Inc 2.14% $25.7 +4.47%+4.90%+7.13%
IMNM Immunome Inc 1.85% $19.55 +1.24%-6.46%-20.75%
GILD Gilead Sciences Inc 1.74% $151.17 +2.77%+4.44%+5.18%
EXAS Exact Sciences Corp 1.59% $104.91 +0.95%+1.29%+1.43%
TWST Twist Bioscience Corp 1.56% $159.78 +5.08%-15.31%+25.59%
ARWR Arrowhead Pharmaceuticals Inc 1.54% $62.75 +3.31%-2.24%-24.26%
KRYS Krystal Biotech Inc 1.53% $331.61 +1.32%+2.89%-4.44%
VRTX Vertex Pharmaceuticals Inc 1.39% $510.08 +1.36%+1.06%-1.04%
TXG 10X Genomics Inc 1.39% $80.65 +4.36%-13.74%+17.58%
GMAB Genmab A/S 1.28% $37.07 +2.83%+6.68%+14.17%
AGIO Agios Pharmaceuticals Inc 1.27% $31.81 -0.34%+0.03%-5.33%
VCYT Veracyte Inc 1.20% $45.23 +3.74%-1.27%+10.67%
CTVA Corteva Inc 1.18% $13.24 -3.71%+11.07%-84.22%
REGN Regeneron Pharmaceuticals Inc 1.16% $746.54 +0.94%+1.54%-4.47%
ARGX Argenx SE 1.09% $825.03 +0.78%-10.25%-16.19%
BMRN BioMarin Pharmaceutical Inc 1.09% $54.8 -0.17%-4.17%-16.57%
BMY Bristol-Myers Squibb Co 1.08% $59.12 -0.77%-3.32%-7.10%
DHR Danaher Corp 1.08% $219.81 +1.08%+2.69%+9.83%
RGEN Repligen Corp 1.06% $173.88 +6.13%-4.30%+5.27%
NTLA Intellia Therapeutics Inc 1.06% $13.07 +3.73%+6.61%+11.33%
TEM Tempus AI Inc 1.03% $70.93 +2.38%-7.44%+20.20%
VKTX Viking Therapeutics Inc 1.00% $28.51 +2.81%-4.78%-10.85%
DAR Darling Ingredients Inc 1.00% $60.26 -3.20%-4.26%-7.45%
ABSI Absci Corp 0.99% $10.16 +13.65%-8.22%+23.75%
SANA Sana Biotechnology Inc 0.91% $2.79 +0.00%-3.46%-10.86%
DNA Ginkgo Bioworks Holdings Inc 0.82% $13 +14.64%+5.26%+92.59%
EDIT Editas Medicine Inc 0.75% $2.9 +2.11%+10.69%+7.41%
EXEL Exelixis Inc 0.74% $59.86 +1.42%+2.52%+6.66%
ACLX Arcellx Inc 0.73% $115.07 +0.03%+0.06%+0.44%
ZTS Zoetis Inc 0.73% $74.81 +2.37%+7.35%+2.52%
BIIB Biogen Inc 0.71% $225.71 +3.33%+2.65%+3.94%
ALLO Allogene Therapeutics Inc 0.70% $1.46 +4.29%-2.67%-17.98%
MRK Merck & Co Inc 0.70% $145.6 +2.26%+0.90%+1.16%
ARCT Arcturus Therapeutics Holdings 0.68% $13.74 +6.76%+5.45%-6.72%
HALO Halozyme Therapeutics Inc 0.67% $110.42 +0.53%+0.51%+3.00%
IOVA Iovance Biotherapeutics Inc 0.64% $14.62 +9.84%+2.85%+70.00%